David Miklos, MD, PhD, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
David Miklos, MD, PhD, clinical director of the CAR T-Cell Therapy Program and Associate Professor of Medicine at the Stanford University Medical Center, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
The ZUMA-2 trial was for patients with mantle cell lymphoma (MCL) who had failed 2 prior lines of therapy and were refractory to BTK inhibitors, and Miklos says that once a patient fails the BTK inhibitor, the patients are usually not able to achieve long-term remissions.
He highlights the overall response rate and complete remission in the trial, and the durable response rate for patients who had follow-up of 2 years. MCL has an important leukemic stage in which physicians could use blood-based next-generation sequencing technologies such as the ClonoSEQ assay to detect the number of cancer cells in a patient, Miklos says, and a portion of the patients in ZUMA-2 who were tested that way showed undetectable minimal residual disease.